BR112016007588A2 - formas de dosagem farmacêutica compreendendo sódio 1-[6- (morfolina-4-il) pirimidina-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato - Google Patents

formas de dosagem farmacêutica compreendendo sódio 1-[6- (morfolina-4-il) pirimidina-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato

Info

Publication number
BR112016007588A2
BR112016007588A2 BR112016007588A BR112016007588A BR112016007588A2 BR 112016007588 A2 BR112016007588 A2 BR 112016007588A2 BR 112016007588 A BR112016007588 A BR 112016007588A BR 112016007588 A BR112016007588 A BR 112016007588A BR 112016007588 A2 BR112016007588 A2 BR 112016007588A2
Authority
BR
Brazil
Prior art keywords
morpholin
triazol
pyrazol
pyrimidin
dosage forms
Prior art date
Application number
BR112016007588A
Other languages
English (en)
Inventor
Winter Gabriele
Neumann Heike
Benke Klaus
Formell Michael
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49356354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016007588(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of BR112016007588A2 publication Critical patent/BR112016007588A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

resumo formas de dosagem farmacêutica compreendendo sódio 1-[6- (morfolina-4-il) pirimidina-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato a presente invenção refere-se a formas de dosagem farmacêutica sólida para administração oral compreendendo sódio 1-[6-(morfolina-4-il) pirimidina-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato (ingrediente ativo (i)), caracterizado pelo fato de que o ingrediente ativo (i) é libertado, e também os métodos para a sua preparação, à sua utilização como medicamentos, e também a sua utilização para a profilaxia, profilaxia secundária ou tratamento de distúrbios, particularmente os distúrbios cardiovasculares, insuficiência cardíaca, anemia, doenças renais crônicas e insuficiência renal.
BR112016007588A 2013-10-17 2014-10-13 formas de dosagem farmacêutica compreendendo sódio 1-[6- (morfolina-4-il) pirimidina-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato BR112016007588A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13189145 2013-10-17
PCT/EP2014/071855 WO2015055564A1 (de) 2013-10-17 2014-10-13 Pharmazeutische darreichungsformen enthaltend natrium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olat

Publications (1)

Publication Number Publication Date
BR112016007588A2 true BR112016007588A2 (pt) 2017-09-12

Family

ID=49356354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007588A BR112016007588A2 (pt) 2013-10-17 2014-10-13 formas de dosagem farmacêutica compreendendo sódio 1-[6- (morfolina-4-il) pirimidina-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato

Country Status (35)

Country Link
US (1) US9827198B2 (pt)
EP (1) EP3057580B1 (pt)
JP (1) JP6525979B2 (pt)
KR (1) KR102330953B1 (pt)
CN (1) CN105636580B (pt)
AP (1) AP2016009135A0 (pt)
AR (1) AR098064A1 (pt)
AU (1) AU2014336389B2 (pt)
BR (1) BR112016007588A2 (pt)
CA (1) CA2927437C (pt)
CL (1) CL2016000857A1 (pt)
CU (1) CU24515B1 (pt)
DK (1) DK3057580T3 (pt)
DO (1) DOP2016000078A (pt)
EA (1) EA032932B1 (pt)
ES (1) ES2868228T3 (pt)
GT (1) GT201600072A (pt)
HR (1) HRP20210691T1 (pt)
HU (1) HUE054107T2 (pt)
IL (1) IL244933B (pt)
JO (1) JO3645B1 (pt)
LT (1) LT3057580T (pt)
MA (1) MA38974B2 (pt)
MX (1) MX2016004628A (pt)
MY (1) MY190202A (pt)
NI (1) NI201600054A (pt)
PE (1) PE20160669A1 (pt)
PH (1) PH12016500716A1 (pt)
SA (1) SA516370940B1 (pt)
SI (1) SI3057580T1 (pt)
TN (1) TN2016000135A1 (pt)
TW (1) TWI746418B (pt)
UA (1) UA119855C2 (pt)
UY (1) UY35784A (pt)
WO (1) WO2015055564A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3845230B1 (en) * 2018-08-31 2023-07-12 Astellas Pharma Inc. Pharmaceutical composition for oral administration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
BRPI0808889A2 (pt) * 2007-03-13 2014-11-11 Dainippon Sumitomo Pharma Co Comprimido desintegrante oral
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
CU24515B1 (es) 2021-05-12
MY190202A (en) 2022-04-04
AU2014336389B2 (en) 2020-01-30
WO2015055564A1 (de) 2015-04-23
GT201600072A (es) 2018-12-19
JO3645B1 (ar) 2020-08-27
PH12016500716B1 (en) 2016-06-20
TN2016000135A1 (en) 2017-10-06
NI201600054A (es) 2016-09-21
LT3057580T (lt) 2021-04-12
PE20160669A1 (es) 2016-08-04
SI3057580T1 (sl) 2021-07-30
CA2927437A1 (en) 2015-04-23
SA516370940B1 (ar) 2019-11-20
UA119855C2 (uk) 2019-08-27
CU20160048A7 (es) 2016-10-28
EA201690788A1 (ru) 2016-09-30
TWI746418B (zh) 2021-11-21
ES2868228T3 (es) 2021-10-21
MX2016004628A (es) 2016-08-01
IL244933B (en) 2020-11-30
JP6525979B2 (ja) 2019-06-05
JP2016538256A (ja) 2016-12-08
KR102330953B1 (ko) 2021-11-26
KR20160068784A (ko) 2016-06-15
CN105636580A (zh) 2016-06-01
AU2014336389A1 (en) 2016-05-12
AP2016009135A0 (en) 2016-04-30
AR098064A1 (es) 2016-04-27
HRP20210691T1 (hr) 2021-06-11
EA032932B1 (ru) 2019-08-30
DK3057580T3 (da) 2021-05-10
EP3057580A1 (de) 2016-08-24
CA2927437C (en) 2022-06-28
CN105636580B (zh) 2020-03-31
IL244933A0 (en) 2016-05-31
US9827198B2 (en) 2017-11-28
UY35784A (es) 2015-05-29
NZ718063A (en) 2021-06-25
HUE054107T2 (hu) 2021-08-30
US20160256394A1 (en) 2016-09-08
PH12016500716A1 (en) 2016-06-20
TW201607568A (zh) 2016-03-01
DOP2016000078A (es) 2016-08-15
MA38974B2 (fr) 2020-11-30
MA38974A1 (fr) 2017-05-31
CL2016000857A1 (es) 2016-11-25
EP3057580B1 (de) 2021-02-24

Similar Documents

Publication Publication Date Title
BR112015018168A2 (pt) inibidores de rock suaves
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
ECSP13012627A (es) 1h-pirazol-5-olato sódico sustituido
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
BR112015021097A2 (pt) formulações de compostos orgânicos
DOP2019000072A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
BR112016007588A2 (pt) formas de dosagem farmacêutica compreendendo sódio 1-[6- (morfolina-4-il) pirimidina-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
CL2015002951A1 (es) Silicato de zirconio microporoso y diuréticos para la reducción de potasio y el tratamiento de una enfermedad crónica del riñón y/o crónica del corazón.
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
CR20160177A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)1h-pirazol-5-olato de sodio
HRP20230105T1 (hr) N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti
RU2016148285A (ru) Способ профилактики послеродовых заболеваний у коров
BR112015018930A2 (pt) benzamidas substituídas com atividade para receptores ep4
TH161044B (th) ไทร(เฮเทอโร)เอริล ไพราโซล และการใช้ของมัน
BR112016002176A2 (pt) novos compostos de indazol e um processo para a sua preparação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements